MorphoSys AG (MORG.DE)

About

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.78
Market Cap(Mil.):	€2,171.58
Shares Outstanding(Mil.):	29.35
Dividend:	--
Yield (%):	--

Financials

	MORG.DE	Industry	Sector
P/E (TTM):	--	85.68	32.76
EPS (TTM):	-2.61	--	--
ROI:	-19.28	1.79	14.61
ROE:	-19.78	3.28	16.33

Latest News about MORG.DE

German stocks - Factors to watch on September 13

BERLIN, Sept 13 The following are some of the factors that may move German stocks on Thursday:

13 Sep 2018

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

19 Jul 2018

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

19 Jul 2018

German stocks - Factors to watch on July 11

BERLIN/FRANKFURT, July 11 The following are some of the factors that may move German stocks on Wednesday:

11 Jul 2018

German stocks - Factors to watch on June 13

FRANKFURT/BERLIN, June 13 The following are some of the factors that may move German stocks on Wednesday:

13 Jun 2018

German stocks - Factors to watch on May 17

BERLIN/FRANKFURT, May 17 The following are some of the factors that may move German stocks on Thursday:

17 May 2018

BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR

* Q1 REVENUE 2.8 MILLION EUR VERSUS 11.8 MILLION EUR YEAR AGO

02 May 2018

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

01 May 2018

BRIEF-MorphoSys Announces Approval Of Tremfya(R)In South Korea

* DGAP-NEWS: MORPHOSYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) IN SOUTH KOREA

26 Apr 2018

BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million

* DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION

23 Apr 2018

» More MORG.DE News